Biocair (Cambridge, UK) has created a specialist logistics team to meet the complex needs of the rapidly expanding cell and gene therapy (CGT) sector.
The company is continuing to develop a team of over 30 dedicated specialists to deliver 24-hour global support for cell and gene therapy service users, it is reported.
The investment, says Biocair, will position the company “at the forefront of personalized logistics, connecting innovative drug developers with patients.”
Biocair plans to double the size of the team over the next 12 months. The company plans to recruit personnel in key regions, including Europe, the Middle East and Africa (EMEA), Asia-Pacific (APAC) and the US over the next five years. The CGT market was valued at USD4.99 billion in 2021 and is forecast to reach USD 36.92 billion by 2027.
Biocair UK Cell and Gene Therapy Lead, Kinga Lovasz, commented: “This new team of experts will enhance Biocair’s agility in the field and enable us to develop new logistics solutions, such as advanced packaging and tracking technologies, to ensure materials arrive on-time and in-full anywhere across the globe.”